JP6214537B2 - 貧血患者の貧血の要因を検出するためのバイオマーカー - Google Patents
貧血患者の貧血の要因を検出するためのバイオマーカー Download PDFInfo
- Publication number
- JP6214537B2 JP6214537B2 JP2014531657A JP2014531657A JP6214537B2 JP 6214537 B2 JP6214537 B2 JP 6214537B2 JP 2014531657 A JP2014531657 A JP 2014531657A JP 2014531657 A JP2014531657 A JP 2014531657A JP 6214537 B2 JP6214537 B2 JP 6214537B2
- Authority
- JP
- Japan
- Prior art keywords
- acvr2b
- anemia
- determining
- antibody
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000007502 anemia Diseases 0.000 title claims description 141
- 239000000090 biomarker Substances 0.000 title claims description 36
- 238000000034 method Methods 0.000 claims description 123
- 210000005259 peripheral blood Anatomy 0.000 claims description 100
- 239000011886 peripheral blood Substances 0.000 claims description 100
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 66
- 208000032839 leukemia Diseases 0.000 claims description 61
- 239000008280 blood Substances 0.000 claims description 59
- 210000004369 blood Anatomy 0.000 claims description 55
- 239000000032 diagnostic agent Substances 0.000 claims description 34
- 229940039227 diagnostic agent Drugs 0.000 claims description 34
- 210000003743 erythrocyte Anatomy 0.000 claims description 34
- 210000000265 leukocyte Anatomy 0.000 claims description 19
- 108010052946 Activin Receptors Proteins 0.000 claims description 11
- 102000018918 Activin Receptors Human genes 0.000 claims description 11
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 11
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 4
- 206010067959 refractory cytopenia with multilineage dysplasia Diseases 0.000 claims 6
- 206010038270 Refractory anaemia with an excess of blasts Diseases 0.000 claims 3
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 claims 3
- 208000032411 Refractory with Excess of Blasts Anemia Diseases 0.000 claims 3
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 description 99
- 208000009527 Refractory anemia Diseases 0.000 description 23
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 230000004069 differentiation Effects 0.000 description 17
- 201000010099 disease Diseases 0.000 description 15
- 238000005259 measurement Methods 0.000 description 13
- 238000000691 measurement method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 210000000601 blood cell Anatomy 0.000 description 9
- 210000003924 normoblast Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000001995 reticulocyte Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 102100035716 Glycophorin-A Human genes 0.000 description 6
- 108091005250 Glycophorins Proteins 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- -1 kit Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 101150031865 ACVR2B gene Proteins 0.000 description 5
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 206010058314 Dysplasia Diseases 0.000 description 4
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 4
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010059616 Activins Proteins 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 102100026818 Inhibin beta E chain Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000488 activin Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 2
- 101001054832 Homo sapiens Inhibin beta C chain Proteins 0.000 description 2
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100027004 Inhibin beta A chain Human genes 0.000 description 2
- 102100026812 Inhibin beta C chain Human genes 0.000 description 2
- 108010004250 Inhibins Proteins 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 229960005552 PAC-1 Drugs 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000040856 WT1 Human genes 0.000 description 2
- 108700020467 WT1 Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000024389 cytopenia Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000000893 inhibin Substances 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 101150084579 GATA1 gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 description 1
- 101001076604 Homo sapiens Inhibin alpha chain Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 description 1
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025885 Inhibin alpha chain Human genes 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 102100032999 Integrin beta-3 Human genes 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000003167 anti-vitamin Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003013 erythroid precursor cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000045412 human ACVR2B Human genes 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108010019691 inhibin beta A subunit Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 238000000125 metastable de-excitation spectroscopy Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012182058 | 2012-08-21 | ||
| JP2012182058 | 2012-08-21 | ||
| PCT/JP2013/072335 WO2014030683A1 (fr) | 2012-08-21 | 2013-08-21 | Biomarqueur pour la détection d'un facteur pour l'anémie chez un patient anémique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2014030683A1 JPWO2014030683A1 (ja) | 2016-07-28 |
| JP6214537B2 true JP6214537B2 (ja) | 2017-10-25 |
Family
ID=50149989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014531657A Expired - Fee Related JP6214537B2 (ja) | 2012-08-21 | 2013-08-21 | 貧血患者の貧血の要因を検出するためのバイオマーカー |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP6214537B2 (fr) |
| WO (1) | WO2014030683A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015228843A (ja) * | 2014-06-06 | 2015-12-21 | 公益財団法人神奈川科学技術アカデミー | 生体内の鉄量に関する状態を予測する方法 |
| CN115327118A (zh) * | 2022-09-05 | 2022-11-11 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Cd38+hla-dr+cd8+t细胞在gvhd早期诊断中的应用 |
| CN115524490B (zh) * | 2022-10-24 | 2023-08-22 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Hla-dr+cd14+cd56+单核细胞在aa或hlh中诊断的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11335399A (ja) * | 1998-05-20 | 1999-12-07 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 新規モノクローナル抗体 |
| US20030219846A1 (en) * | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| CN101198321A (zh) * | 2005-04-26 | 2008-06-11 | 味之素株式会社 | 骨髓祖红细胞分化诱导剂 |
| WO2008076437A2 (fr) * | 2006-12-18 | 2008-06-26 | Acceleron Pharma Inc. | Antagonistes de l'activine-actrii et ses utilisations pour accroître les niveaux de globules rouges |
| DK3750552T5 (da) * | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| MY153078A (en) * | 2009-04-27 | 2014-12-31 | Novartis Ag | Compositions and methods for increasing muscle growth |
-
2013
- 2013-08-21 WO PCT/JP2013/072335 patent/WO2014030683A1/fr active Application Filing
- 2013-08-21 JP JP2014531657A patent/JP6214537B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2014030683A1 (ja) | 2016-07-28 |
| WO2014030683A1 (fr) | 2014-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shi et al. | Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease | |
| Garratty et al. | Correlation between in vivo hemolysis and the amount of red cell‐bound IgG measured by flow cytometry | |
| Yamaoka et al. | The immature platelet fraction is a useful marker for predicting the timing of platelet recovery in patients with cancer after chemotherapy and hematopoietic stem cell transplantation | |
| EP2215480B1 (fr) | Outils diagnostiques et thérapeutiques pour maladies altérant la fonction vasculaire | |
| Sakuragi et al. | Clinical significance of IPF% or RP% measurement in distinguishing primary immune thrombocytopenia from aplastic thrombocytopenic disorders | |
| Sicard et al. | Computer-assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection | |
| Torres et al. | Circulating endothelial cells in patients with venous thromboembolism and myeloproliferative neoplasms | |
| MX2014000804A (es) | Ensayo para capturar y detectar celulas circulantes de mieloma multiple de la sangre. | |
| Belotti et al. | Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65‐75 years | |
| JP6214537B2 (ja) | 貧血患者の貧血の要因を検出するためのバイオマーカー | |
| Reis-Alves et al. | Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors | |
| US10914748B2 (en) | Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease | |
| Manivannan et al. | Diagnosis of paroxysmal nocturnal hemoglobinuria: recent advances | |
| Djamiatun et al. | Increase of plasminogen activator inhibitor-1 and decrease of transforming growth factor-β1 in children with dengue haemorrhagic fever in Indonesia | |
| Michur et al. | Reticulated platelets as a marker of platelet recovery after allogeneic stem cell transplantation | |
| Timofeeva | Donor-specific HLA antibodies as biomarkers of transplant rejection | |
| Eller et al. | Advances in the diagnosis and treatment in kidney transplantation | |
| KR102262248B1 (ko) | 허혈성 뇌경색에의 다능성 줄기 세포의 동원 | |
| CA2941460C (fr) | Vesicules extracellulaires derivees d'erythrocyte comme biomarqueur d'evaluation clinique de maladie de parkinson | |
| Ahmedy et al. | Role of CD305 and CD38 in chronic lymphocytic leukemia clinical relevance | |
| Jaing et al. | Assessment of platelet activation and immature platelet fraction as predictors of platelet engraftment after hematopoietic stem cell transplantation | |
| WO2020250593A1 (fr) | Procédé de prédiction d'une réaction du greffon contre hôte (gvhd) et ordinateur permettant la prédiction d'une gvhd | |
| WO2020010189A1 (fr) | Procédés et compositions pour analyser des plaquettes par cytométrie de masse | |
| Gavazza et al. | Hematological ratios and indices in canine large B-cell lymphoma | |
| EP4057004A1 (fr) | Procédé d'acquisition d'informations sur l'amyotrophie spinale |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160809 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170321 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170519 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170829 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170919 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6214537 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |